Satellos Bioscience Inc.
corporate_fare Company Profile
Satellos Bioscience Inc. (NASDAQ:MSLE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for MSLE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for MSLE spans 6-K, 40-F.
Recent high-impact activity:
- Satellos Posts Q3 Loss of $11.2M, $53.0M Cash Through 2027, Health Canada Clears FSHD CTA
- Satellos Switches BASECAMP Primary Endpoint to MRI Fat Fraction After FDA Feedback
- Satellos Completes BASECAMP Phase 2 Enrollment, Delays Topline Data to Q1 2027
- Satellos Gets FDA Clearance to Test Forazapadin in FSHD, Secures $5M Non-Dilutive Funding
- Satellos Reports Q2 2026 Loss of $11.7M, Cash Runway Through 2027, and Positive TRAILHEAD Data
Short Interest & Short Volume
3.86 days to coverFINRA reported short interest of 127,108 shares in MSLE as of the October 30, 2026 settlement, a 30.7% increase from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 39.0% of MSLE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
MSLE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.